Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Jan 11, 2021 (filed on Jan 13, 2021)Insider Name:Meresman Stanley JOwnership Type:Direct OwnershipSecurities:STOCK OPTION (RIGHT TO BUY)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,934Price:--
- Jan 11, 2021 (filed on Jan 13, 2021)Insider Name:Meresman Stanley JOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,934Price:$142.00
- Jan 11, 2021 (filed on Jan 13, 2021)Insider Name:Meresman Stanley JOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,934Price:$5.94
- Jan 06, 2021 (filed on Jan 07, 2021)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-279,127Price:$129.54
- Jan 06, 2021 (filed on Jan 07, 2021)Insider Name:Talasaz AmirAliOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-279,127Price:$129.54
- Jan 04, 2021 (filed on Jan 06, 2021)Insider Name:Clark Ian TOwnership Type:Direct OwnershipSecurities:STOCK OPTION (RIGHT TO BUY)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,690Price:--
- Jan 04, 2021 (filed on Jan 06, 2021)Insider Name:Clark Ian TOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,690Price:$129.23
- Jan 04, 2021 (filed on Jan 06, 2021)Insider Name:Clark Ian TOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,690Price:$4.18
- Jan 01, 2021 (filed on Jan 05, 2021)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:Performance-Based Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-565,192Price:--
- Jan 01, 2021 (filed on Jan 05, 2021)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:565,192Price:--
Filings by filing date
- Jan 11, 2021 (filed on Jan 13, 2021)Insider Name:Meresman Stanley JOwnership Type:Direct OwnershipSecurities:STOCK OPTION (RIGHT TO BUY)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,934Price:--
- Jan 11, 2021 (filed on Jan 13, 2021)Insider Name:Meresman Stanley JOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,934Price:$142.00
- Jan 11, 2021 (filed on Jan 13, 2021)Insider Name:Meresman Stanley JOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:4,934Price:$5.94
- Jan 06, 2021 (filed on Jan 07, 2021)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-279,127Price:$129.54
- Jan 06, 2021 (filed on Jan 07, 2021)Insider Name:Talasaz AmirAliOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-279,127Price:$129.54
- Jan 04, 2021 (filed on Jan 06, 2021)Insider Name:Clark Ian TOwnership Type:Direct OwnershipSecurities:STOCK OPTION (RIGHT TO BUY)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,690Price:--
- Jan 04, 2021 (filed on Jan 06, 2021)Insider Name:Clark Ian TOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,690Price:$129.23
- Jan 04, 2021 (filed on Jan 06, 2021)Insider Name:Clark Ian TOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,690Price:$4.18
- Jan 01, 2021 (filed on Jan 05, 2021)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:Performance-Based Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-565,192Price:--
- Jan 01, 2021 (filed on Jan 05, 2021)Insider Name:Eltoukhy HelmyOwnership Type:Direct OwnershipSecurities:COMMON STOCKNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:565,192Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 505 Penobscot Dr REDWOOD CITY CA 94063-4737 |
Tel: | 1-415-9375405 |
Website: | www.guardanthealth.com |
IR: | See website |
Key People | ||
AmirAli Talasaz Chairman of the Board, President, Chief Operating Officer | Helmy A. Eltoukhy Chief Executive Officer, Director | Michael Bell Chief Financial Officer |
Kumud Kalia Chief Information Officer | Michael J. Wiley Chief Legal Officer |
Business Overview |
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval. |
Financial Overview |
For the nine months ended 30 September 2020,Guardant Health Inc revenues increased 38% to $208.4M. Netloss increased from $50.4M to $160M. Revenues reflectUnited States segment increase of 42% to $191.6M,International segment increase of 1% to $16.8M. Higher netloss reflects Stock-based Compensation in increase from$3.7M to $72.6M (expense), Research and development expenseincrease of 83% to $102.2M (expense). |
Employees: | 622 as of Dec 31, 2019 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $14,709M as of Sep 30, 2020 |
Annual revenue (TTM): | $271.31M as of Sep 30, 2020 |
EBITDA (TTM): | -$163.90M as of Sep 30, 2020 |
Net annual income (TTM): | -$185.25M as of Sep 30, 2020 |
Free cash flow (TTM): | -$128.84M as of Sep 30, 2020 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 99,972,386 as of Oct 31, 2020 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |